We have read the interesting paper recently published in *Critical Care*\[[@B1]\]. In the issue of pharmacodynamics of β-lactams we missed a particular subject: allergy, subtle but sometimes important in intensive and critical care units since clinicians usually manage patients labelled as \'allergic\' without having been studied and based only on clinical history \[[@B2]\]. This creates a health resource problem and leads to use alternative treatments in most cases with a higher cost \[[@B3]\].

We would like to contribute in this issue by describing our experience of reaching a reliable diagnosis in subjects assessed for immediate drug allergy reaction (2001 to 2010) \[[@B2]\]. Diagnosis was supported by a skin test \[[@B4]\], and if skin tests were negative by a single-blind drug challenge test \[[@B5]\] (see Table [1](#T1){ref-type="table"}). Nursing and physician staff were present with full resuscitation delivery.

###### 

Diagram for diagnosis of penicillin allergy

  β-lactam                                                                 Skin prick test (mg/ml)                                         Intradermal (mg/ml)   Provocation test (mg)
  ------------------------------------------------------------------------ --------------------------------------------------------------- --------------------- ------------------------
  Penicillins                                                              PPL 5×10^-5^mmol/l; MDM 2×10^-2^mmol/l; penicillin G 20-25^a^   As SPT                5, 25, 100, 250, 500
  Aminopenicillins (amoxicillin, ampicillin, cloxacillin) Cephalosporins   PPL 5×10^-5^mmol/l; MDM 2×10^-2^mmol/l; penicillin G 20-25^a^   As SPT                5, 25, 100, 250, 500
   Oral (cefaclor, cefadroxil, cefixime, cefuroxime)                       2-100                                                           2^a^                  5, 25, 125, 500
   Intravenous (cefazolin, ceftriaxone, ceftazidine)                       2-100                                                           2^a^                  5, 25, 100, 500, 1,000

Diagnosis was supported by skin test (ST) (skin prick and intradermal test) \[[@B5],[@B6]\], and if STs were negative by a single-blind drug challenge test (DChT) with increasing doses of the suspected drug \[[@B3],[@B4]\] every 60 minutes until the usual daily dose was administered or symptoms occurred (some of the symptoms previously described were present) \[[@B2]\]. If symptoms appeared more than 3 hours after the last dose of the DChT, a new DChT was proposed and scheduled. PPL, major determinant of penicillin (Diater Lab, Madrid, Spain); MDM, minor determinant mixture of penicillin (Diater Lab); SPT, skin prick test. ^a^From Torres and colleagues \[[@B7]\].

The results are shown in Table [2](#T2){ref-type="table"}, with 3,426 total studies involving antibiotics, 4,867 drug challenge tests performed, and 159 positive cases (7%) with β-lactams. Only 114 patients were not studied (refusal or rejected). Unquestionably, the most problematic group of antibiotics was penicillins, including aminopenicillins. It is remarkable that 21 patients with a negative skin test suffered a positive oral drug challenge test, more evident in the latter studied period, possibly explained by the lower sensitivity of the skin test for the most currently used aminopenicillins.

###### 

Data for drug allergy studies 2001 to 2010

  ----------------------------------------------------------------------
  Group               2001 to\   2006 to\     Total         Percentage
                      2005       2010                       
  ------------------- ---------- ------------ ------------- ------------
  Penicillins         676 (76)   1,329 (75)   2,025 (151)   7.4

   Skin prick test    676 (10)   1,329 (08)   \(18\)        

   Intradermal test   676 (62)   1,329 (50)   \(112\)       

   Challenge          604 (4)    1,271 (17)   \(21\)        

  Cephalosporins      24 (2)     160 (3)      184 (5)       2.7

   Skin prick test    24 (2)     160 (2)      \(4\)         

   Challenge          22 (0)     158 (1)      \(1\)         

  Others^a^           82 (1)     38 (2)       120 (3)       2.5

   Skin prick test    82 (1)     38 (1)       \(2\)         

   Challenge          81 (0)     37 (1)       \(1\)         

  Total               782        1,527        2,309 (159)   6.9
  ----------------------------------------------------------------------

Data presented as total number of patients (number of patients diagnosed positive). Symptoms were not limited only to the skin (urticaria, erythema, angioedema), but also included confusion, collapse, unconsciousness, hypotension, diaphoresis, vomiting, presyncope, dyspnoea, stridor, wheeze, chest/throat tightness, nausea/vomiting, and abdominal pain. ^a^Included carbapenems (imipinem, meropenem) and monobactams (aztreonam).

Finally, we would like to encourage allergological studies for an accurate diagnosis of drug allergy, a common problem in clinical practice that can influence the decisions on prescription drugs.
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